Genzyme and Relational Investors: Science and Business Collide?
Publication date: 20 January 2017
Abstract
The chairman and CEO of the Genzyme Corporation, one of the country's top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.
Keywords
Citation
Eades, K.M., Matos, P. and Green, R. (2017), "Genzyme and Relational Investors: Science and Business Collide?", . https://doi.org/10.1108/case.darden.2016.000132
Publisher
:University of Virginia Darden School Foundation
Copyright © 2011 by the University of Virginia Darden School Foundation, Charlottesville, VA. All rights reserved.